XML 24 R13.htm IDEA: XBRL DOCUMENT
v3.5.0.2

Warrants | 9 Months Ended
--- | ---
Sep. 30, 2016
Warrants [Abstract] |
Warrants | 7. Warrants ﻿ On January 4, 2016, the Company entered into an Asset Purchase Agreement with Novolytics Limited (the “Purchase Agreement”), to purchase certain preclinical materials and intangible assets, including patent rights, from Novolytics, an unrelated third party. In consideration for the assets acquired, the Company paid cash consideration of approximately $205,000 and issued warrants to purchase an aggregate of 170,000 shares of the Company’s common stock. The warrants have an exercise price of $12.00 per share and contain certain registration rights. The fair value of the warrants issued was $204,000, based on a Monte Carlo valuation model and are classified as equity within the consolidated balance sheet s. The Company expensed the total value provided for the acquired assets of $409,000 as in-process research and development as of the acquisition date given there was no alternative future use of the acquired assets due to the early stage nature of the technology and pre-clinical materials. ﻿ On April 8, 2016, the Company modified 315,244 warrants held by the Holders, in accordance with the terms of the CSIA (see Note 6). ﻿ On June 3, 2016, the Company issued warrants exercisable for an aggregate of 1,063,830 shares of common stock at an exercise price of $2.25 per share in connection with the closing of a registered public offering of common stock and warrant s (see Note 8). ﻿ The following table provides a summary of warrants outstanding, issued or exercised for the nine months ended September 30, 2016. Also included is the average exercise price per share and the aggregate proceeds to the Company if exercised as of September 30, 2016. ﻿ ﻿
﻿ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
﻿ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
﻿ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
﻿ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
﻿ |  |  | $2.25 |  | $4.05 - $8.25 |  | $10.75 - $23.00 |  | Totals
﻿ |  |  |  |  | Weighted |  |  |  |  | Weighted |  |  |  |  | Weighted |  |  |  |  | Weighted
﻿ |  |  |  |  | Average |  |  |  |  | Average |  |  |  |  | Average |  |  |  |  | Average
﻿ |  |  |  |  | Exercise |  |  |  |  | Exercise |  |  |  |  | Exercise |  |  |  |  | Exercise
﻿ |  |  | Shares |  | Price |  | Shares |  | Price |  | Shares |  | Price |  | Shares |  | Price
﻿Balance, December 31, 2015 | - |  | - |  | $ | - |  |  | 694,062 |  | $ | 5.82 |  |  | 515,587 |  | $ | 11.39 |  |  | 1,209,649 |  | $ | 8.19
﻿Issuances |  |  | 1,063,830 |  |  | 2.25 |  |  | - |  |  | - |  |  | 170,000 |  |  | 12.00 |  |  | 1,233,830 |  |  | 3.59
﻿Exercises | - |  | - |  |  | - |  |  | - |  |  | - |  |  | - |  |  | - |  |  | - |  |  | -
﻿Balance, September 30, 2016 |  |  | 1,063,830 |  | $ | 2.25 |  |  | 694,062 |  | $ | 5.82 |  |  | 685,587 |  | $ | 11.54 |  |  | 2,443,479 |  | $ | 5.87
﻿ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
﻿Aggregate proceeds if exercised |  | $ | 2,393,618 |  |  |  |  | $ | 4,036,474 |  |  |  |  | $ | 7,914,572 |  |  |  |  | $ | 14,344,664 |  |  |
﻿

X
- Definition The entire disclosure for stockholders equity warrants and rights. + References No definition available. + Details
Name: | aphb_StockholdersEquityNoteWarrantsDisclosureTextBlock
Namespace Prefix: | aphb_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_WarrantsAndRightsNoteDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration